Please assess the completion status of the following clinical trial:

Trial Title: TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with symptomatic orthostatic hypotension due to Parkinson's disease, multiple system atrophy, or pure autonomic failure, (i.e. neurogenic orthostatic hypotension).~* At screening, subject must meet the diagnostic criteria of neurogenic orthostatic hypotension, as demonstrated by a ≥ 30 mm Hg drop in systolic blood pressure (SBP) within 5 minutes of standing.~* Impaired autonomic reflexes, as determined by absence of BP overshoot during phase IV of the Valsalva maneuver, in subjects where Valsalva is performed, as appropriate.~* For the optional open-label extension study subjects must have demonstrated a pressor effect and completed dosing in Part A.~Exclusion Criteria:~* Systemic illnesses known to produce autonomic neuropathy, including but not limited to diabetes mellitus, amyloidosis, monoclonal gammopathy of unknown significance, and autoimmune neuropathies.~* Concomitant use of vasoconstricting agents for the purpose of increasing BP such as ephedrine, dihydroergotamine, or midodrine must be stopped at least 2 days or five half lives (whichever is longer) prior to dosing on Day 1 of Part A and C, and throughout the duration of Part C. Subjects previously enrolled in Part A under previous versions of the protocol will continue taking fludrocortisone during the washout period and in Part C at the dose and regimen used in Part A. For new subjects enrolling in Part A under Amendment 3, fludrocortisone use in both Parts of the study and during the washout period will be limited to 0.1 mg QD.~* Concomitant use of anti-hypertensive medication for the treatment of essential hypertension unrelated to autonomic dysfunction.~* Known or suspected alcohol or substance abuse within the past 12 months.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TD-9855 Part A (Type: EXPERIMENTAL): Subjects will receive placebo and escalating single doses of TD-9855
- TD-9855 Part B (Type: EXPERIMENTAL): Subjects will receive a single dose of TD-9855 or placebo.
- TD-9855 Part C (Type: EXPERIMENTAL): Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).